Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers

Stopped early · Phase 1/Phase 2

Conditions studied: Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific

In brief

RATIONALE: Vaccines made from gene-modified tumor cells may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of tumor cells. Combining vaccine therapy with cyclophosphamide and interferon alfa may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining vaccine therapy with interferon alfa and cyclophosphamide in treating patients who have stage IV breast cancer.

Key facts

Study ID

NCT00095862

Run by

Wiseman Research Initiatives LLC

People needed

24

Starts

2004-11-01

Last updated by the study team

2018-02-05

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Glendale Memorial Hospital Comprehensive Cancer Center — Glendale, California, United States
• Hollywood Presbyterian Medical Center — Los Angeles, California, United States
• Study site — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.